Lineage Cell Therapeutics’ (LCTX) Buy Rating Reaffirmed at HC Wainwright
HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a report released on Tuesday morning,Benzinga reports. The firm currently has a $9.00 target price on the stock. LCTX has been the topic of several other research reports. Maxim Group lowered their price objective on Lineage Cell Therapeutics […]
HC Wainwright reissued their buy rating on shares of Lineage Cell Therapeutics (NYSEAMERICAN:LCTX – Free Report) in a report released on Tuesday morning,Benzinga reports. The firm currently has a $9.00 target price on the stock. LCTX has been the topic of several other research reports. Maxim Group lowered their price objective on Lineage Cell Therapeutics […]
